20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
Vaxxinity Inc (NASDAQ:VAXX) unveiled results from Part B of its Phase 1 clinical trial of UB-312, an investigational vaccine for Parkinson's disease (PD).
UB-312 is a synthetic peptide vaccine targeting aggregated forms of aSyn, which plays a central role in PD development and progression.
UB-312 was well-tolerated and induced anti-alpha-synuclein (aSyn) antibody responses in participants with early PD, meeting the trial's primary objectives.
92% of patients (12 out of 13) who completed dosing with UB-312 developed anti-aSyn antibodies.
The results demonstrate important features for immunotherapy against PD and represent a proof-of-principle for Vaxxinity's platform in chronic disease.
UB-312 was well-tolerated, and antibodies were detectable in cerebrospinal fluid.
UB-312 safely broke immune tolerance, induced antibodies against toxic forms of alpha-synuclein, and showed potential target engagement in the periphery and crossing the blood-brain barrier.
The trial was not designed to measure differences in PD progression between UB-312 and placebo groups.
The Michael J. Fox Foundation is funding a collaborative project to evaluate the potential of UB-312 further and characterize the produced anti-aSyn antibodies.
Price Action: VAXX shares are down 2.38% at $2.05 on the last check Thursday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!